Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?

Wieneke Dijk, Cédric Le May, Bertrand Cariou

Journal: Trends in endocrinology and metabolism: TEM 2019;29(6):420-434

PMID: 29665987

Full Text on Elsevier Science View on PubMed

Abstract

Elevated plasma triglyceride (TG) levels are an independent risk factor for cardiovascular disease (CVD). Proprotein convertase subtilisin-kexin 9 (PCSK9) - a protein therapeutically targeted to lower plasma cholesterol levels - might regulate plasma TG-rich lipoprotein (TRL) levels. We provide a timely and critical review of the current evidence for a role of PCSK9 in TRL metabolism by assessing the impact of PCSK9 gene variants, by reviewing recent clinical data with PCSK9 inhibitors, and by describing the potential mechanisms by which PCSK9 might regulate TRL metabolism. We conclude that the impact of PCSK9 on TRL metabolism is relatively modest, especially compared to its impact on cholesterol metabolism.

Address: L'institut du thorax, INSERM, CNRS, Université de Nantes, Nantes, France.; L'institut du thorax, INSERM, CNRS, Université de Nantes, Nantes, France; L'institut du thorax, Department of Endocrinology, CHU NANTES, Nantes, France. Electronic address: [email protected].

DOI: 10.1016/j.tem.2018.03.013

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/29665987

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3369

Subscription / membership required

Full Text Sources:

MeSH Terms: Apolipoproteins B, Humans, Lipid Metabolism, Lipoproteins, LDL, Proprotein Convertase 9, Proprotein Convertases